295 related articles for article (PubMed ID: 36248712)
41. Diagnostic accuracy of anti-phospholipase A2 receptor (PLA2R) antibodies in idiopathic membranous nephropathy: an Italian experience.
Porcelli B; Guarnieri A; Ferretti F; Garosi G; Terzuoli L; Cinci F; Tabucchi A; Tampoia M; Abbracciavento L; Villani C; Deleonardi G; Grondona AG; Mazzolini M; La Manna G; Santostefano M; Infantino M; Manfredi M; Spatoliatore G; Rosati A; Somma C; Bizzaro N
J Nephrol; 2021 Apr; 34(2):573-579. PubMed ID: 33123964
[TBL] [Abstract][Full Text] [Related]
42. The cutoff value and prognosis of anti-PLA2R antibody for idiopathic membranous nephropathy: a single-center retrospective study in China.
Guo H; Yao Y; Zhou J; Wang S; Wang Y; Zheng D
Ren Fail; 2023; 45(2):2253922. PubMed ID: 37724562
[TBL] [Abstract][Full Text] [Related]
43. Clinicopathological Features of Idiopathic Membranous Nephropathy in 33 Adolescents.
Li C; Li H; Wen YB; Li JN; Lin WF; Cai JF; Duan L; Li Y; Li XM; Li XW
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Aug; 39(4):544-551. PubMed ID: 28877834
[TBL] [Abstract][Full Text] [Related]
44. A comparison of clinical features between idiopathic membranous nephropathy patients with and without serum antibody against phospholipase A2 receptor.
Zhang Q; Liu X; Zhang Z; Wu M; Huang B; Zhang Y; Liu B; Qi Z; Shan W; Wang L; Hu Z; Sun Z
Medicine (Baltimore); 2019 Nov; 98(45):e17658. PubMed ID: 31702617
[TBL] [Abstract][Full Text] [Related]
45. Clinicopathological characteristics and prognosis of hepatitis B associated membranous nephropathy and idiopathic membranous nephropathy complicated with hepatitis B virus infection.
Wang R; Wu Y; Zheng B; Zhang X; An D; Guo N; Wang J; Guo Y; Tang L
Sci Rep; 2021 Sep; 11(1):18407. PubMed ID: 34526634
[TBL] [Abstract][Full Text] [Related]
46. Effect of rituximab in patients with PLA2R-associated membranous nephropathy and malignancy.
Guo Y; Ren M; Wang Y; Zhai Z; Yu L; Wang L; Tang L
Int Immunopharmacol; 2024 Jan; 126():111327. PubMed ID: 38056198
[TBL] [Abstract][Full Text] [Related]
47. Cyclophosphamide induced early remission and was superior to rituximab in idiopathic membranous nephropathy patients with high anti-PLA2R antibody levels.
Xue C; Wang J; Pan J; Liang C; Zhou C; Wu J; Song S; Cui L; Zhang L; Liu Y; Dai B
BMC Nephrol; 2023 Sep; 24(1):280. PubMed ID: 37740193
[TBL] [Abstract][Full Text] [Related]
48. Clinicopathological characteristics and outcomes of PLA2R related idiopathic membranous nephropathy in patients with seronegative PLA2R antibodies.
Li X; Shen Y; Li Y; Ma L; Sun Q
Ren Fail; 2024 Dec; 46(1):2297015. PubMed ID: 38275176
[TBL] [Abstract][Full Text] [Related]
49. Clinicopathological Characteristics and Outcomes of PLA
Luo J; Yuan Y; Tian J; Zhou Z; Su C; Yang F; Wang G
Am J Kidney Dis; 2022 Sep; 80(3):364-372. PubMed ID: 35288217
[TBL] [Abstract][Full Text] [Related]
50. Anti-phospholipase A2 receptor antibody levels at diagnosis predicts outcome of TAC-based treatment for idiopathic membranous nephropathy patients.
Wang B; Zhu Z; Huang F; Huang H; Tu L; Wang Y; Zheng L; Zhou J; Wei X
BMC Nephrol; 2022 Sep; 23(1):306. PubMed ID: 36068486
[TBL] [Abstract][Full Text] [Related]
51. [Anti-phospholipase A2 receptor (anti-PLA2R) antibodies and idiopathic membranous nephropathy: which role in diagnosis and prognosis of this disease?].
Netti GS; Ranieri E
G Ital Nefrol; 2014; 31(3):. PubMed ID: 25030016
[TBL] [Abstract][Full Text] [Related]
52. Anti-PLA2R Antibody Levels and Clinical Risk Factors for Treatment Nonresponse in Membranous Nephropathy.
Barbour SJ; Fervenza FC; Induruwage D; Brenchley PE; Rovin B; Hladunewich MA; Reich HN; Lafayette R; Aslam N; Appel GB; Zand L; Kiryluk K; Liu L; Cattran DC;
Clin J Am Soc Nephrol; 2023 Oct; 18(10):1283-1293. PubMed ID: 37471101
[TBL] [Abstract][Full Text] [Related]
53. Negative anti-phospholipase A2 receptor antibody status at three months predicts remission in primary membranous nephropathy.
Stefan G; Stancu S; Zugravu A; Popa O; Zubidat D; Petre N; Mircescu G
Ren Fail; 2022 Dec; 44(1):258-268. PubMed ID: 35172682
[TBL] [Abstract][Full Text] [Related]
54. [Expression of renal PLA2R in patients with idiopathic membranous nephropathy and its relationship with the curative effect of immunotherapy].
Wang LJ; Shang MH; Zhuge YF; Huang YX; Rong S; Tang ZH; Bao JF; Yu Q; Yuan WJ
Zhonghua Yi Xue Za Zhi; 2016 Jan; 96(1):4-8. PubMed ID: 26792599
[TBL] [Abstract][Full Text] [Related]
55. Hypercholesterolemia Correlates With Glomerular Phospholipase A2 Receptor Deposit and Serum Anti-Phospholipase A2 Receptor Antibody and Predicts Proteinuria Outcome in Idiopathic Membranous Nephropathy.
Dong L; Li YQ; Guo SM; Xu G; Wei W; Han M
Front Immunol; 2022; 13():905930. PubMed ID: 35784308
[TBL] [Abstract][Full Text] [Related]
56. Combination of Rituximab and Low-dose Tacrolimus in the Treatment of Refractory Membranous Nephropathy: A Retrospective Cohort Study.
Chen X; Jiao S; Li S; Li J; Li P; Song F; Yan Z
Balkan Med J; 2023 Jul; 40(4):287-293. PubMed ID: 37260416
[TBL] [Abstract][Full Text] [Related]
57. IgG4 anti-phospholipase A2 receptor might activate lectin and alternative complement pathway meanwhile in idiopathic membranous nephropathy: an inspiration from a cross-sectional study.
Yang Y; Wang C; Jin L; He F; Li C; Gao Q; Chen G; He Z; Song M; Zhou Z; Shan F; Qi K; Ma L
Immunol Res; 2016 Aug; 64(4):919-30. PubMed ID: 26837241
[TBL] [Abstract][Full Text] [Related]
58. Optimized rituximab regimen versus recommended regimen for idiopathic membranous nephropathy: A single-center retrospective cohort study.
Yan P; Fang X; Ke B
Int Immunopharmacol; 2024 Mar; 130():111718. PubMed ID: 38377859
[TBL] [Abstract][Full Text] [Related]
59. Prognostic value of PLA2R autoimmunity detected by measurement of anti-PLA2R antibodies combined with detection of PLA2R antigen in membranous nephropathy: A single-centre study over 14 years.
Pourcine F; Dahan K; Mihout F; Cachanado M; Brocheriou I; Debiec H; Ronco P
PLoS One; 2017; 12(3):e0173201. PubMed ID: 28257452
[TBL] [Abstract][Full Text] [Related]
60. Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy.
Kanigicherla D; Gummadova J; McKenzie EA; Roberts SA; Harris S; Nikam M; Poulton K; McWilliam L; Short CD; Venning M; Brenchley PE
Kidney Int; 2013 May; 83(5):940-8. PubMed ID: 23364522
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
